MetaCap

Innoviva (INVA) vs Rapport Therapeutics (RAPP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Innoviva (INVA) has outperformed Rapport Therapeutics (RAPP) over the past year, losing 12.2% versus a loss of 15.0%. Rapport Therapeutics is the larger company by market cap ($1.37 billion vs $1.31 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INVA-12.17%RAPP-15.01%
+98%+38%-23%
Nov 21, 20251 yearNov 20, 2026
INVA+14.06%RAPP+11.35%
+144%+37%-70%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INVA versus RAPP key metrics
MetricINVARAPP
Share price$18.41$23.16
Market cap$1.31B$1.37B
1-day change0.00%-1.82%
YTD return-7.90%-23.67%
1-year return-12.17%-15.01%
5-year return+8.81%—
P/E ratio (TTM)7.83—
Forward P/E8.33—
EPS (TTM)$2.35$-3.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$411.33M—
Revenue growth (YoY)+14.67%—
Net income (latest FY)$271.17M$-111.48M
Gross margin74.80%—
Operating margin39.81%—
Net margin65.92%—
52-week high$25.15$52.93
52-week low$18.19$22.06
Distance from 52-week high-26.80%-56.24%
Analyst consensusbuystrong_buy
Avg. price target upside+89.03%+177.25%
Average volume865.66K790.62K
Shares outstanding71.08M59.28M
Employees15984
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Innoviva

INVA stock →

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

INVA vs RAPP FAQ

Which is bigger, Innoviva or Rapport Therapeutics?

Rapport Therapeutics (RAPP) is larger, with a market capitalization of $1.37B compared with $1.31B for Innoviva (INVA).

Which stock has performed better over the past year, INVA or RAPP?

INVA returned -12.17% over the past 12 months, compared with -15.01% for RAPP (price return, excluding dividends). Past performance does not predict future results.

Are Innoviva and Rapport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons